The main event in blood coagulation is the thrombincatalyzed conversion of fibrinogen into fibrin. This singular transformation of a soluble protein into an insoluble polymeric network occurs with faultless precision. Abnormalities of fibrin polymerization can lead to hemorragic and thrombotic disorders. Increased fibrinogen plasma concentration (Fg) and fibrin polymerization rate (FPR) could be additional risk factors associated with atherothrombosis in antiphospholipid syndrome (APS) and in systemic lupus erythematosus (SLE). Our objective was to investigate Fg and FPR in consecutive patients with APS and SLE. Thirty-nine patients and 31 ageand gender-matched healthy controls were studied. Sixteen patients
The antiphospholipid syndrome (APS) is an acquired thrombophilic disorder. During coagulation, the platelet negatively charged phospholipids serve as a template for the formation of an enzyme-cofactor substrate complex in a regulated sequence, culminating with the transformation of fibrinogen into fibrin by thrombin action. During this process, proteins bound to the phospholipid surfaces adopt new configurations and expose neoepitopes, eliciting an immunologic response, giving rise to the generation of antiphospholipid antibodies (aPL). These antibodies may *Department of Rheumatology, tDepartment of Hematology, Tepartment of Endocrinology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico. had primary APS, 13 patients had SLE, and 10 patients had SLE plus APS. The mean of the FPR was significantly increased (0.2799 ± 0.091) in patients with APS plus SLE as compared with the control group (0.2052 ± 0.055) (p<0.05). Fg was higher in APS plus SLE (3.15 g/L ± 0.43) and in primary APS (3.03 g/L ± 0.29) than in controls (2.87 g/L ± 0.49). Our results demonstrated an increased FPR in patients with APS plus SLE. This phenomenon could be an additional risk factor for thrombosis in these autoimmune diseases. Key Words: Fibrinogen-Fibrin polymerization rate-Antiphospholipid syndrome-Systemic lupus erythematosus. interfere with the procoagulant or anticoagulant activities of the target protein-phospholipid complexes (1) . The most frequently aPL found until now, are against the apolipoprotein B2 glycoprotein 1, prothrombine, and the components of protein C pathway 1. Recent evidence has suggested that the immune response against B2 glycoprotein 1 may play a role in atherogenesis and APS and has been described as a "crossroads of autoimmunity and atherosclerosis" (2, 3) . On the other hand, the natural history of systemic lupus erythematosus (SLE) is complicated by atherosclerosis and related vascular diseases (4) (5) (6) .
Atherosclerosis is a systemic arterial disease with arterial narrowing, characterized by endothelial dysfunction, altered vascular relaxation, and hemostatic imbalance. The atherosclerotic vessel wall features accumulation of lipids, lipoproteins, and inflammatory cells such as macrophages and T lymphocytes on the intima, and smooth muscle cell proliferation (7) . An inflammatory reaction in the atheroma, seen in early atherosclerotic lesions, is a determinant factor for the development of complications of atherosclerotic disease such as thrombosis.
Risk factors predisposing to arterio-thrombotic phenomena in autoimmune diseases like APS and SLE include the lupus anticoagulant, antiphospholipid antibodies, anti-oxidized low-density lipoprotein antibodies, inhibitory antibodies against protein C and protein S, activated protein C resistance, and increased levels of lipoprotein (a). These may occur in addition to the conventional risk factors of arteriosclerosis. Recently described risk factors, including fibrinogen increase, must also be considered (8) .
Our objective was to evaluate and compare fibrinogen levels and fibrin polymerization rate (FPR) in patients with primary APS and in patients with SLE with or without an associated APS.
PATIENTS AND METHODS
We studied 39 consecutive patients that attended the rheumatology clinic of our institution. Sixteen patients had primary APS, 13 patients had SLE, and ten patients had APS plus SLE. Results were compared with those of 31 age-and gender-matched controls. The diagnosis of APS was based on the classification criteria established in Sapporo in 1998 (9) and the diagnosis of SLE was based on the American College of Rheumatology (ACR 1992) classification criteria (10) . All the patients were receiving oral anticoagulants to an International Normalized Ratio between 2.5 and 3.0. Patients with a history of thrombotic events in the 6 months before the study were excluded.
Blood Samples
Preprandial blood was collected by venipuncture into polypropylene tubes containing 1:9 vol/vol 3.8% (0.129 mol/L) trisodium citrate as anticoagulant. The samples were centrifugated at 2500 x g for 15 minutes. After centrifugation, plasma was drawn off carefully using a plastic pipette and a plastic tube. For fibrinogen determinations plasma was stored at 2°C to 8°C (crushed ice) and the testing was completed within 4 hours of sample collection. For FPR determinations, the poor-platelet plasma samples were frozen at -700C until the performance of the test.
Fibrinogen
The fibrinogen concentration was determined by the chronometric assay by Clauss (11) . It is based on the clotting time of a mixture of diluted plasma and a standarized thrombin solution; the reagent used was Fibriquik Organon Teknika, in a photo-optical instrument Coag-a-Mate XM Organon Teknika.
The recorded clotting times depend on the plasma concentration of functional fibrinogen. The plasma dilution reduces the influence of inhibitors, i.e. heparin, but not the retarding effects of fibrin-digested products. When thrombin is added to a sample of plasma, fibrinogen is converted enzymatically to fibrin, which in turn undergoes polymerization to form a fibrin network. Factor XIII, activated by thrombin, stabilize cross links to produce a clot. The elapsed time from addition of thrombin to the formation of a clot is inversely proportional to fibrinogen level.
The fibrinogen values in grams per liter are obtained by comparing the clotting times of unknown plasma samples 1:10 diluted in sodium barbital buffer, 0.028 M, pH 7.35 (Owren's veronal buffer) with serial dilutions (1:5, 1:10, 1:20, 1:40) of a reference plasma with known clottable fibrinogen concentration. Double logarithmic paper is used to plot times on the ordinate against the concentration (g/L) on the abcissa. If the clotting time indicates a very high level of fibrinogen, the 1:20 dilution was used rather than the 1:10 dilution and the interpolated value was multiply by 2 to correct the greater dilution. The normal range of plasma fibrinogen by clotting assays is 1.7 to 4.0 g/L.
Fibrin Polymerization Rate Determination
Plasma samples were defrosted in blocks at 37°C to eliminate variability between interassay groups, and were diluted 1:9 with NaCl 0.154 M solution; 400 AL from this solution were deposited in a microcell for optical density reading; 200 ,LL of bovine thrombine (Baxter) were added for a 0.5 U/mL final concentration. The reading was performed in a Shimadzu spectrophotometer UV 160U at 350 nm, with a reference filter at 650 nm. The FPR was determined as the slope of absorbance versus time logarithm. Results were compared between groups.
For all variables, the mean and SD or the median and range were calculated. Comparisons between groups were evaluated with parametric or nonparametric analysis of variance.
The statistical analysis was performed with the SPSSS program for Windows.
RESULTS
There were no significant differences in demographic data (Table 1 ) and body mass index among groups. The group with primary APS and the group with APS plus SLE had higher fibrinogen levels than the group with SLE and the control group. The highest fibrinogen levels were observed in patients with APS plus SLE, while they were similar in SLE and controls ( Table 2) .
The FPR was elevated in all patient groups when compared to the controls (p<0.05). The FPR was similar in patients with SLE and patients with primary APS. The greatest acceleration of FPR was observed in patients with APS plus SLE (p<0.05) ( Fig. 1) .
DISCUSSION
We studied a small but representative group of patients with primary APS and patients with SLE with and without associated APS, and controls. Female gender predominated in all groups and there were no significant differences in demographics among groups. Our results show that FPR is accelerated in patients with primary APS, SLE, and APS plus SLE, as compared to healthy controls. Greatest acceleration of FPR was observed in patients with APS plus SLE. Highest fibrinogen levels were also observed in this group, suggesting that FPR acceleration could be a consequence of increased fibrinogen levels. While similar fibrinogen levels were observed in SLE patients and controls, FPR in the SLE group was greater than that in the controls. Consequently, these phenomena could be explained by additional mechanisms including biochemical factors, as well as subtle differences in the quality of fibrinogen and fibrin molecules that might accelerate or delay FPR.
Fibrinogen is the most abundant protein of blood coagulation and is a powerful predictor of cerebrovascular and cardiovascular diseases (12, 13) . Patients with a history of myocardial infarction or stroke have increased fibrinogen levels when compared to controls (14) . In the general population with fibrinogen within the normal range, an increase of 60 mg/dL of fibrinogen has been associated with an 80% increase in the vascular disease risk (15) . High fibrinogen level >3.43 g/L had a twofold increase in myocardial risk (16) . Fibrinogen is atherogenic by increasing blood viscosity, promoting platelets aggregation, and stimulating smooth muscle cells proliferation (12) . Fibrinogen levels are increased in acute inflammation (17) . Fibrinogen levels are increased in SLE with or without associated APS, although a relationship between fibrinogen levels and disease activity has not been shown (6) . On the other hand, fibrinogen levels increase after menopause, with age, with body mass, with steroids use, in diabetes mellitus, in smokers, with increased LDL cholesterol, with increased Lp(a), with the leukocyte count, and are higher in men and African Americans (12, (18) (19) (20) (21) (22) . (23) . Fibrin deposits stimulate endothelial cells cytokine release, which may in turn stimulate fibrinogen hepatic synthesis (24) as well as fibrin substrate by an unfavorable positive feedback mechanism. In SLE, thrombin generation is increased especially in disease relapses (25, 26) , the fibrinolytic potential is low and may persist in inactive disease (27) (28) (29) , and fibrin turnover is increased (24) . Under these circumstances, an increased fibrinogen synthesis may increase blood viscosity and have deleterious effects on microcirculation. Interestingly, blood viscosity is particularly increased in SLE patients with a poor prognosis (30, 31) . To our knowledge, ours is the first study of FPR in rheumatic diseases. There are limitations in our study. One is the small number of patients and controls. Another limitation is that we have not investigated additional thrombogenic factors. Larger, prospective studies will be required to better understand the possible role of FPR as a risk factor for atherothrombotic phenomena. In summary, we have observed an acceleration of FPR in patients with SLE and primary APS, conditions associated with atherothrombosis. When both conditions co-exist, the FPR is even more accelerated. The highest fibrinogen levels were also observed in this group, which suggests that FPR acceleration might result from this increase, although more specific studies are needed to determine the nature of this relationship. 
